Sorafenib in Treating Nonsmokers or Former Light Smokers with Relapsed or Refractory Stage IIIB or Stage IV NSCLC

Article

This trial seeks to evaluate the efficacy of sorafenib in treating nonsmokers or former light smokers who have relapsed or refractory stage IIIB or stage IV NSCLC.

Study Type: Interventional

Age/Sex Requirements: 18 years+ (None)

Sponsor: Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

ClinicalTrials.gov Identifier: NCT00754923

Purpose: Sorafenib is a drug that may stop tumor cell growth by blocking blood flow to the tumor and certain necessary enzymes. This trial seeks to evaluate the efficacy of sorafenib in treating nonsmokers or former light smokers who have relapsed or refractory stage IIIB or stage IV NSCLC. The study will also evaluate progression-free survival at 6 months as well as overall survival, and will assess toxicity and mutational status.

Click here to learn more about this clinical trial.

Related Videos
Video 10 - "Future Treatment Landscape for COPD"
Video 9 - "Emerging Treatment Approaches in COPD"
A panel of 4 experts on HIV
A panel of 4 experts on HIV
Kelly Nichols, OD; Laura Periman, MD; and Mile Brujic, OD
What Makes JAK Inhibitors Safe in Dermatology
Potential JAK Inhibitor Combination Regimens in Dermatology
Therapies in Development for Hidradenitis Suppurativa
"Prednisone without Side Effects": The JAK Inhibitor Ceiling in Dermatology
© 2024 MJH Life Sciences

All rights reserved.